Workflow
ACCO(ACCO) - 2025 Q4 - Annual Report
2026-03-09 20:28
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-08454 ACCO Brands Corporation (Exact Name of Registrant as Specified in Its Charter) (S ...
Greenlight Re(GLRE) - 2025 Q4 - Annual Results
2026-03-09 20:28
GREENLIGHT RE ANNOUNCES FINANCIAL RESULTS FOR FOURTH QUARTER AND YEAR-END DECEMBER 31, 2025 Improves Q4 Combined Ratio to 92.1%, Achieves Record Full-Year Underwriting Income. GRAND CAYMAN, Cayman Islands – March 9, 2026 – Greenlight Capital Re, Ltd. (NASDAQ: GLRE) ("Greenlight Re" or the "Company") today reported its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Highlights (all comparisons are to fourth quarter 2024 unless noted otherwise): https://event.web ...
netpower(NPWR) - 2025 Q4 - Annual Report
2026-03-09 20:27
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 001-40503 NET Power Inc. (Exact name of registrant as specified in its charter) Delaware 98-1580612 (State or other jurisd ...
Zevra Therapeutics(ZVRA) - 2025 Q4 - Annual Report
2026-03-09 20:23
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________________________________________ FORM 10-K ______________________________________________________________________ x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Com ...
Kempharm(KMPH) - 2025 Q4 - Annual Report
2026-03-09 20:23
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________________________________________ FORM 10-K ______________________________________________________________________ x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Com ...
NL Industries(NL) - 2025 Q4 - Annual Results
2026-03-09 20:20
NL REPORTS FOURTH QUARTER 2025 RESULTS DALLAS, TEXAS – March 9, 2026 – NL Industries, Inc. (NYSE: NL) today reported a net loss attributable to NL stockholders of $31.0 million, or $.63 per share, in the fourth quarter of 2025 compared to net income attributable to NL stockholders of $16.5 million, or $.34 per share, in the fourth quarter of 2024. NL's results include an unrealized loss of $4.5 million in the fourth quarter of 2025 compared to an unrealized loss $12.0 million in the fourth quarter of 2024 r ...
Vicarious Surgical (RBOT) - 2025 Q4 - Annual Results
2026-03-09 20:17
Exhibit 99.1 Vicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial Results WALTHAM, Mass.-- (BUSINESS WIRE) – March 9, 2026 – Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (OTCID: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Results In accordance with guidance provided by the SEC rega ...
Kronos(KRO) - 2025 Q4 - Annual Results
2026-03-09 20:17
KRONOS WORLDWIDE, INC. REPORTS FOURTH QUARTER 2025 RESULTS DALLAS, TEXAS…March 9, 2026…Kronos Worldwide, Inc. (NYSE:KRO) today reported a net loss of $82.8 million, or $.72 per share, in the fourth quarter of 2025 compared to a net loss of $13.2 million, or $.12 per share, in the fourth quarter of 2024. For the full year of 2025, Kronos Worldwide reported a net loss of $110.9 million, or $.96 per share, compared to net income of $86.2 million, or $.75 per share, for the full year of 2024. Our net loss incre ...
netpower(NPWR) - 2025 Q4 - Annual Results
2026-03-09 20:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2026 NET POWER INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 320 Roney St., Suite 200 Durham, North Carolina 27701 (Address of principal executive offices) (Zip Code) ...
Anixa Biosciences(ANIX) - 2026 Q1 - Quarterly Report
2026-03-09 20:16
Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2026 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-37492 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other ju ...